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Abstract
Background: Currently existing yellow fever (YF) vaccines are based on the live attenuated yellow fever virus 17D strain
(YFV-17D). Although, a good safety profile was historically attributed to the 17D vaccine, serious adverse events have been
reported, making the development of a safer, more modern vaccine desirable.
Methodology/Principal Findings: A gene encoding the precursor of the membrane and envelope (prME) protein of the
YFV-17D strain was inserted into the non-replicating modified vaccinia virus Ankara and into the D4R-defective vaccinia
virus. Candidate vaccines based on the recombinant vaccinia viruses were assessed for immunogenicity and protection in a
mouse model and compared to the commercial YFV-17D vaccine. The recombinant live vaccines induced c-interferon-
secreting CD4- and functionally active CD8-T cells, and conferred full protection against lethal challenge already after a
single low immunization dose of 10
5 TCID50. Surprisingly, pre-existing immunity against wild-type vaccinia virus did not
negatively influence protection. Unlike the classical 17D vaccine, the vaccinia virus-based vaccines did not cause mortality
following intracerebral administration in mice, demonstrating better safety profiles.
Conclusions/Significance: The non-replicating recombinant YF candidate live vaccines induced a broad immune response
after single dose administration, were effective even in the presence of a pre-existing immunity against vaccinia virus and
demonstrated an excellent safety profile in mice.
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Introduction
Yellow fever (YF) still represents a substantial threat to public
health in endemic regions of tropical Africa and South America.
The World Health Organization (WHO) estimated that 200,000
cases occur annually with 30,000 fatalities [1]. The causative agent
ofthe disease,yellowfevervirus(YFV),a single strandedRNAvirus,
belongs to the family of the Flaviviridae and is transmitted by
mosquitoes [2]. Yellow fever disease can be divided into three
stages. After an incubation period of 3–6 days, patients develop
febrile illness with symptoms like fever, malaise, lower backpain,
headache, myalgia, nausea, vomiting, and prostration lasting 3–4
days. Symptoms normally disappear for 2–48 hours before 15–25%
of the patients enter the third phase, the period of intoxication,
characterized by fever, vomiting, epigastric pain, hemorrhagic
diathesis, jaundice, and liver and renal failure. Death occurs in 20–
50% of severe YF cases on the seventh to tenth day [3–6].
As early as 1937, a live attenuated vaccine strain, yellow fever
17D, was developed based on the Asibi wild-type strain by passage
in mouse and chick tissue cultures [7,8]. The 17D vaccine has
been used for many decades and has been administered to more
than 400 million people [5]. The 17D vaccine, formerly classified
as one of the most effective and safest available [9] is now
considered to be less safe [10]. Recent studies revealed a number
of vaccine related serious adverse events (SAE). Per 100,000
vaccinations 0.8 subjects developed vaccine-associated neurotropic
disease [11] and 1 in 200,000 to 400,000 vaccinees developed
viscerotropic disease [10]. Within the major traveler group, i.e.
people over 60 years of age, the SAE incidence rate for
viscerotropic disease is 1 for every 50,000 vaccinations [10].
Additionally, serious adverse outcomes, including death, have
been reported in Spain, Brazil, United States, Australia, and
Thailand across all age groups [12–18]. These reports emphasize
that there is a need for a vaccine with an improved safety profile.
The YFV envelope (E) protein plays a dominant role in the
induction of a protective immune response. In animal studies,
purified E protein or recombinant vaccinia virus expressing prME
induce high levels of neutralizing antibodies and confer immunity
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expressing only non-structural YFV proteins were only partially
protective [21]. Additionally, passive transfer of monoclonal anti-E
antibodies demonstrated that antibody mediated immunity was
sufficient to protect mice [22]. In an attempt to develop a YFV
vaccine that predominantly targets the humoral immune response,
an inactivated whole virus vaccine approach has recently been
described [23]. However, studies indicating an important role for
cellular immune responses in protection have also been published.
CD4 lymphocytes bearing a Th1 phenotype in combination with
antibodies were reported to play a critical role in virus clearance
[24]. CD8 T cells that were induced by YFV-17D exhibited all
characteristics necessary for protective cellular immunity, such as
broad specificity, robust proliferation, high magnitude, and long
term persistence [25,26]. A high number of CD8- and CD4-
specific T cell epitopes were mapped in the envelope protein [27–
29].
Recombinant vaccines based on modified vaccinia virus Ankara
(MVA) [30] have been used in many non clinical and clinical
studies (see for instance refs. [31–34]). MVA has proven to be
exceptionally safe [35]. No significant side effects were observed
when MVA was administered to more than 120 000 humans in
the context of the smallpox eradication campaign [36,37]. Safety
was also confirmed for several MVA-vectored recombinant
vaccines in clinical studies [31–34,38]. Due to a block in virion
morphogenesis the highly attenuated vaccinia virus strain fails to
productively replicate in human and most other mammalian cells
[39–41]. Nevertheless, the ability of the virus to express viral and
foreign genes in the early and late stage is retained. These
characteristics make MVA a promising live vaccine vector that
induces humoral and cellular immune responses and demonstrates
a high safety profile. Another non-replicating vaccinia virus, the
D4R defective vaccinia virus (dVV), was generated by targeted
deletion of the essential vaccinia virus uracil DNA glycosylase gene
(D4R), which is involved in viral DNA synthesis. Thus, in wild-
type cells, the replication cycle is blocked at the stage of viral
genomic replication prior to late gene expression. For propagation
of dVV, an engineered cell line is used, that complements the
deleted viral D4R function [42,43]. Due to this well-defined
deletion the non-replicating virus dVV represents a safe vaccine
vector [44].
In this study, two new candidate vaccines were developed based
on the non-replicating vaccinia viruses MVA and dVV, both
expressing the YFV-17D prME open reading frame. The
immunogenicity and safety of these vectors were evaluated in
comparison to a commercially available YFV-17D vaccine in
mice. Both candidate vaccines, induced YFV specific humoral and
cellular immune responses at levels similar to the classical 17D
vaccine and protected mice against a lethal YFV challenge even
when pre-immunized with wild-type vaccinia virus. Notably, the
vaccinia-vectored candidate vaccines showed a much better safety
profile in mice than the presently used YFV-17D vaccine.
Materials and Methods
Ethics statement
All animal experiments were reviewed by the Baxter Bioscience
Institutional Animal Care and Use Committee (IACUC Vienna/
Orth) and approved by internal animal welfare officers (Experi-
ment ID 05/07/NO ¨ ). Animal experiments were conducted in
accordance with Austrian laws on animal experimentation and
approved by Austrian regulatory authorities (permit number the
Government of Lower Austria, LF1-TVG-31/005-2007). Exper-
iments were conducted according to guidelines set out by the
Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC). Animals were housed
according to EU guidelines, in housing facilities accredited by the
AAALAC.
Viruses and cell lines
The modified vaccinia virus Ankara [30] was obtained from the
National Institutes of Health (MVA1974/NIH clone 1) and the
vaccinia virus strain Lister/Elstree (VR-862) from the American
Type Culture Collection (ATCC). The origin of the YFV-17D
(17D) strain was the commercially available vaccine Stamaril
(Sanofi/Pasteur). Primary chicken embryo cells (CEC) were
generated from 12 days old chicken embryos and grown in
Medium 199 (Gibco) containing 5% fetal calf serum (FCS),
100 UI/ml Pen/Strep (Lonza) and 100 UI/ml NEAA (Lonza).
Vero (CCL-81), DF-1 (CCL-12203), Sol8 (CRL-2174) and HeLa
(CCL-2) cell lines were obtained from the ATCC. The generation
of the cell line cVero22 has been described earlier [42]. All cell
lines were grown in DMEM (Biochrom) containing 5% FCS,
100 UI/ml Pen/Strep (Lonza) and 100 UI/ml NEAA (Lonza).
Construction of plasmids
The transfer plasmid for recombination into the deletion III (del
III) region of the MVA genome, was constructed in the following
steps: pd3-Script Pre1. The left and right flanks of the del III region
were amplified by PCR from genomic DNA of wild-type MVA by
using the oligonucleotides oYF-8 (59–GTT AAC AGT TTC CGG
TGA ATG TGT AGA TCC AGA TAG T-39) and oYF-9 (59-
GAA GAC GCT AGC ACT AGT GCG GCC GCT TTG GAA
AGT TTT ATA GG-39) for the right flank, and oYF-10 (59- GCG
GCC GCA CTA GTG CTA GCG TCT TCT ACC AGC CAC
CGA AAG AG-39) and oYF-11 (59-CGT ACG TTA TTA TAT
CCA TAG GAA AGG-39) for the left flank. An overlapping PCR
was performed with these two fragments as templates and the
primers oYF-11 and oYF-8. The fragment was cloned into the
vector pPCR-Script Amp SK (+) (Stratagene) resulting in the
plasmid pd3-Script Pre1. pd3-dlacZ/Notr-MCS. The residual lacZ
sequences and the NotI restriction site at Pos. 1617 of the pPCR-
Script-Amp SK (+) plasmid were removed by BamHI, BsmFI or
by BsiWI, Eel136II and mung bean digestion followed by blunt
end religation resulting in the plasmid pd3-dlacZ/Notr. In order
to introduce a multiple cloning site (NheI, HindIII, AluI, BamHI,
StuI, SpeI, XhoI, NotI) between the vaccinia DNA segments, the
plasmid was cut with NheI and NotI, and a linker consisting of the
annealed oligonucleotides oYF-50 (59- CTA GCG ACA AGC
TTG CAG GAT CCA CTA GGC CTA TAA CTA GTC CGC
TCG AGA TTG C-39) and oYF-51 (59 GGC CGC AAT CTC
GAG CGG ACT AGT TAT AGG CCT AGT GGA TCC TGC
AAG CTT GTC G-39) was inserted, resulting in pd3-dlacZ/Notr-
MCS. pDW2-repeat-delIII. A delIII self repeat (R) of the left MVA
flank [45] was generated to facilitate removal of lacZ/gpt gene
cassette by internal homologous recombination during plaque
purification. The delIII self repeat (220 bp) was amplified by PCR
from pd3-Script using the oligonucleotides oYF-48 (59- CGC
CGT CGA CTA TAT TAG ACA ATA CTA CAA TTA AC -39)
and oYF-49 (59-ATA TGG ATC CTC TAC CAG CCA CCG
AAA G-39) and cloned between the SalI and BamHI sites of
pDW2 [46] downstream of the gpt/lacZ gene cassette.
pd3-lacZ-gpt. The lacZ/gpt delIII self repeat fragment of
pDW2-repeat-delIII was cloned into pd3-lacZ/Notr-MCS using
the HindIII and BamHI restriction sites, resulting to pd3-lacZ-gpt.
pd3-lacZ-mH5-YFprMEco. The open reading frame
encoding the YFV prME (YFprMEco) gene (Accession Number
NC_002031 [47], under the control of the strong early/late
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usage (co) and synthesized (Geneart, Regensburg, Germany). The
synthetic sequence is devoid of vaccinia virus early transcription
stop signals; such signal was introduced immediately downstream
of the coding region. The expression cassette was inserted into the
SpeI/NotI site of pd3-lacZ-gpt resulting in pd3-lacZ-mH5-
YFprMEco (Fig. 1A).
pDW-mH5-YFprMEco. For the generation of D4R-defective
vaccinia viruses, a derivate of the plasmid pDW-2 [46] was
constructed. pDW-2 contains vaccinia virus genomic sequences of
the D3R and D5R genes for homologous recombination and a
lacZ/gpt marker cassette located between tandem DNA repeats
allowing transient selection and blue plaque screening. The
synthetic mH5-YFprMEco gene cassette was inserted into the
XhoI/NotI site of plasmid pDW-2 resulting in pDW-mH5-
YFprMEco (Fig. 1C). The sequence of the promoter and prME
gene cassette was verified by sequence analysis.
Construction and purification of recombinant vaccinia
viruses
MVA-YF (Fig. 1B). Twenty micrograms of pd3-lacZ-mH5-
YFprMEco plasmid were transfected into MVA-infected CEC by
calcium phosphate precipitation. Recombinant virus was selected
using the transient marker stabilization method as described
previously [48,49]. A plaque-purified clone was expanded for large
scale propagation in CEC and was termed MVA-YF.
dVV-YF (Fig. 1D). To generate the recombinant, replication-
deficient vaccinia virus (dVV-YF) twenty micrograms of pDW2-
mH5-YFprMEco were transfected into vaccinia virus Lister/
Elstree infected cVero22 cells [42]. Plaque purifications were done
as described earlier [43]. A plaque-purified isolate of the defective
dVV-YF obtained by this procedure was amplified to large scale in
cVero cells and subjected to further characterization.
Western blot analysis
Expression of the prME protein by the MVA-YF and dVV-YF
recombinants was assessed by Western blotting. To analyse the
expression under permissive conditions, DF-1 cells or, in the case
of the defective recombinant, cVero cells were infected with a
MOI of 0.01 for 4 days. For the analysis under non-permissive
conditions, HeLa or Sol8 cells were infected at a MOI of 10 for
72 h. Cells were infected in parallel with the corresponding wild-
type vaccinia viruses or YFV-17D as controls. Sonicated and heat
treated cell lysates were loaded on 12% polyacrylamidamide gels
(Bio-Rad, Inc) and blotted onto nitrocellulose membrane (Invitro-
gen, Inc). To detect the prME protein, a polyclonal guinea pig (gp)
antiserum against YFV-17D was used. Goat anti-guinea pig
horseradish peroxidase conjugated IgG (Jackson ImmunoRe-
search Laboratories, Inc.) was used as a secondary antibody.
YFV-17D infected HeLa cells (MOI 0.01 for 3 days) served as a
positive control.
Double immunostain assay
To detect potential contaminating wild-type virus or recombi-
nants that lost the ability to express YF antigen, DF-1 cells or
cVero22 cells were cultivated in 6 well plates and infected with 10,
100 or 1000 PFU of the recombinants. Wild-type virus and a
mixture of wild-type virus and the respective recombinant were
used as controls. After 1 h of incubation at 37uCi n5 %C O 2, the
viral inoculum was aspirated, and 3 ml of a 0.5% carboxymeth-
ylcellulose overlay with DMEM, supplemented with 5% FCS, was
added to each well. After 4 days of incubation, the overlay was
removed and the cells were fixed with methanol/aceton (1:1). To
detect plaques of YFV E-protein expressors, a gp antiserum
against YFV-17D was used. Goat anti-guinea pig horseradish
peroxidase conjugated IgG ( Jackson ImmunoResearch Laborato-
ries, Inc.) was used as a secondary antibody. Plaques were
visualized with diaminobenzidine (DAB) solutions including nickel
(Vector Laboratories), resulting in black plaques. To detect MVA
plaques without prME expression, a polyclonal rabbit anti-
vaccinia virus serum was used (lot no. AVVSKP26012006). The
secondary antibody was a goat anti-rabbit peroxidase conjugated
IgG ( Jackson Inc). Plaques were visualized with DAB solution
without nickel, resulting in brown plaques. Black and brown
plaques were counted visually.
Immunization and challenge of animals
Protection. Groups of six Balb/c mice (Charles River) were
immunized with MVA-YF or dVV-YF by intramuscular injections
of the indicated doses in a volume of 50 ml in PBS-0.01% human
serum albumin (HSA) buffer. Control groups were immunized
with wild-type vaccinia viruses or YFV-17D in a volume of 50 ml
in PBS-0.01% HSA or with PBS buffer. Mice were challenged
intracerebrally (i.c.) with 1610
5 TCID50 (.1000 mouse lethal
dose 50 (LD50)) of YFV-17D in TBS-0.01% HSA buffer and
monitored for either 14 or 21 days for clinical symptoms and
survival.
Passive Transfer. For generation of sera, Balb/c mice were
immunized three times (d0, d21, d42) with 1610
7 TCID50 MVA-
YF, dVV-YF, wild-type vaccinia virus or with 1610
6 TCID50
Figure 1. Plasmid transfer vectors (A, C) and genome structures
of MVA-YF (B) and dVV-YF (D). The plasmid vector pd3-lacZ-mH5-
YFprMEco (A) targets the deletion III insertion site in the MVA genome.
To obtain recombinant virus (B) without any auxiliary sequences, the
transient lacZ/gpt screening marker in the plasmid is flanked by a
220 bp self repeat (R) of one of the MVA flanks that mediates removal
of the marker cassette by homologous recombination. The insertion site
for the plasmid vector pDW-mH5-YFprMEco (C) is the region between
the ORFs D3R and D5R in the wild-type Lister/Elstree virus. The lacZ/gpt
marker cassette is located between tandem DNA repeats (R, hatched
boxes) to achieve eventual removal of the marker cassette. The
resulting recombinant defective virus (D) lacks the uracil DNA
glycosylase gene (D4R), and still contains one tandem repeat [45].
Both plasmids contain the human codon-optimized YFV prM and E
coding region under the control of the early/late vaccinia virus mH5
promoter.
doi:10.1371/journal.pone.0024505.g001
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analyzed by 50% plaque reduction neutralization assay (PRNT50).
For passive protection experiments, 8–9 weeks old mice were
injected intraperitoneally (i.p.) with 150 ml undiluted or diluted
sera, respectively. Six hours later, mice were challenged
intracerebrally with 1610
5 TCID50 of YFV-17D and monitored
for 21 days for survival.
Pre-existing immunity. Mice were pre-immunized
intramuscularly in a single or double dose scheme with 2610
6
TCID50 of wild-type MVA or vaccinia virus strain Lister/Elstree
three months before the immunization with the recombinant
viruses or the controls. Immunization with the vaccinia vectored
YF vaccines, and challenge was performed as described above.
Safety. To analyze if the integrated YF prME gene cassette
alters the virulence of the recombinant vaccinia viruses, groups of
6 Balb/c mice were challenged i.c. with 1610
5–1610
7 TCID50 of
dVV-YF, MVA-YF or the corresponding wild-type viruses. As a
control, 1610
1–1610
3 TCID50 of the vaccine strain YFV-17D
were administered intracerebrally.
YFV plaque reduction neutralization assay (YFV-PRNT)
Approximately 3610
5 Vero cells were seeded per well in 6 well
plates and cultured overnight to obtain confluent monolayers. Sera
were complement-inactivated at 56uC for 30 min. Pre-vaccination
serum was tested in 1:10 dilution, to which 100 PFU of YFV-17D
were added. Serial two-fold dilutions of the post-vaccination sera
were mixed with 100 PFU of YFV-17D strain and incubated
overnight at 4uC. The mixture of virus and serum were added to
the Vero cell monolayers and incubated for 1 hour at 37uC.
Virus/serum mixtures were replaced by 0.75% carboxymethyl-
cellulose-DMEM solution, incubated for 4 days and visualized by
immunostaining as described above. The neutralizing antibody
titer is the reciprocal of the highest serum dilution that reduced the
number of viral plaques by at least 50% relative to the pre-
vaccination sera.
Vaccinia plaque reduction neutralization assay (VV-PRNT)
The test for neutralizing antibodies against vaccinia virus was
performed as described above, with the difference that vaccinia
virus strain Lister/Elstree (ATCC VR-862) was used as the target
virus, and neutralization was done at 37uC for 1 hour. VV plaques
were stained with crystal violet.
Detection of antigen-specific T cells in immunized mice
Five Balb/c mice per group were immunized as described
above, spleens were collected at day 28 post-immunization, and
pooled splenocyte cell suspensions were prepared. Vaccine-specific
cell-mediated immunity was evaluated as described previously [42]
using flow cytometric interferon-c (IFN-c) response assays and
analysis of killing of peptide-pulsed target cells by specific CD8 T
cells (VITAL assay). For the intracellular cytokine staining assay,
splenocytes were restimulated using 2 mg/ml of the following
previously described [29] synthetic peptides from the yellow fever
envelope protein: E57–71, E129–143, E133–147 (15mer peptides
recognized by CD4 T cells) and E60–68, E330–338, E332–340
(9mer peptides recognized by CD8 T cells). As negative controls,
cells were also stimulated with 15mer and 9mer peptides from
influenza haemagglutinin, QTKLYQNPTTYISVG and IYST-
VASSL, respectively. Medium control background frequencies
were subtracted. In the VITAL assay, 5-(and-6)-carboxyfluores-
cein diacetate succimidyl ester (CSFE)-stained target cells were
loaded with the 9mer peptides E60–68, E330–338, E332–340 at
2 mM, while 5-(and-6)-(((4-chloromethyl)benzoyl)amino) tetra-
methylrhodamine (CMTMR)-labeled control cells were pulsed
with the H2-K
d -restricted peptide IYSTVASSL from influenza
hemagglutinin.
Statistical analysis
Data were analyzed for statistical difference by performing one-
way analysis of variance (ANOVA, Tukey-Kramer multiple
comparisons test) using the GraphPad Prism software (San Diego,
CA). The differences were considered significant when p,0.05.
Results
Construction and Characterization of the Recombinant
Virus MVA-YF
We constructed a recombinant MVA, designated MVA-YF,
that expresses the prME coding sequence (CDS) of yellow fever
virus strain 17D. The prME CDS under the control of the vaccinia
virus early/late mH5 promoter [50] was chemically synthesized.
This allowed the removal of poxvirus early transcription
termination signals (5TNT) present in the original sequence and
the optimization of the open reading frame for human codon
usage to achieve maximal expression levels in humans without
modifying the amino acid sequence.
To generate MVA-YF, the codon-optimized (co) expression
cassette was inserted into the newly constructed transfer plasmid
pd3-lacZ-gpt resulting in the plasmid pd3-lacZ-mH5-YFprMEco
(Fig. 1A). This plasmid directs the foreign gene into the deletion
III region of MVA by homologous recombination. After several
rounds of plaque purification, initially with, then without, selective
pressure [48] the final recombinant virus, designated MVA-YF,
was obtained (Fig. 1B). This virus contains the prME gene
regulated by the vaccinia virus mH5 promoter in the MVA del III
insertion site and is free of additional foreign sequences.
The absence of wild-type MVA from the recombinant virus was
checked by PCR analysis. This assay confirmed that the
recombinant MVA-YF stock was free from parental wild-type
virus at a detection limit of about 1 plaque forming unit (PFU)
contaminants among 1000 PFU of recombinant virus (data not
shown). To confirm the absence of wild-type MVA on the
phenotype level, a double immunostain assay was performed. For
this purpose, DF-1 cells were infected with MVA-YF, wild-type
MVA or with a 1:1 mixture of both viruses as a control. After
incubation for four days, cells were fixed and stained with an anti-
YFV- followed by an anti-VV- antiserum, resulting in black and
brown plaques, respectively. The MVA-YF infected cells showed
uniformly black foci representing recombinants expressing prME
proteins (Fig. 2A), which indicated that the stock was free from
wild-type MVA or aberrant recombinants without prME expres-
sion (non-expressors). In the wild-type MVA control only brown
foci of non-expressors were seen (Fig. 2B), whereas the MVA-YF/
MVA spike control contained clearly distinguishable brown and
black foci in the expected ratio (Fig. 2C).
Construction and Characterization of the Recombinant
Virus dVV-YF
In parallel, a D4R-defective vaccinia virus (dVV) expressing the
codon-optimized prME CDS was generated. For this purpose, the
mH5-prME cassette was inserted into the plasmid pDW2 resulting
in the transfer plasmid pDW-mH5-YFprMEco (Fig. 1C). This
plasmid was used to construct the non-replicating virus dVV-YF,
in which the YFV prME expression cassette is inserted between
the vaccinia D3R and D5R genes, knocking out the essential D4R
gene. Recombinant virus was generated by infecting D4R-
complementing cVero22 cells with wild-type VV (strain Lister/
Elstree), and by transfection of the recombination plasmid and
MVA-Based Yellow Fever Live Vaccine
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section. These steps resulted in the replication-deficient recombi-
nant virus, termed dVV-YF (Fig. 1D). The recombinant had the
intended genetic structure without any marker gene, as charac-
terized by PCR. It was growth-defective in wild-type cells, and all
plaques analyzed by double immunostaining expressed prME
proteins (data not shown).
Antigen Expression in Permissive- and Non Permissive
Cells
The prME expression pattern by MVA-YF was first tested
under conditions that are permissive for MVA replication. For this
purpose, avian DF-1 cells were infected with a MVA-YF or with
wild-type MVA or YFV-17D as controls at a MOI of 0.01.
Infected cells were incubated for four days and total cell lysates
were investigated by SDS-PAGE and Western blot analysis using
polyclonal anti-YFV-17D antiserum. As shown in Fig. 3A, the YF
envelope (E) protein expressed by the recombinant MVA-YF (lane
1) appeared as a single band in the 55 kDa size range, which is the
expected size of flavivirus E proteins [2]. An identical band was
also detectable in the YFV-17D infection (lane 4). The E protein
expression level of the recombinant MVA was higher than in the
YFV-17D infection. The low expression level of YFV-17D in
avian DF-1 cells was seen repeatedly.
To investigate the prME expression by dVV-YF in a cell culture
system that supports replication of D4R defective vaccinia, the
complementing Vero cell line cVero22 was infected with a MOI of
0.01 with dVV-YF or with the dVV wild-type virus or YFV-17D
as controls. Further steps were performed as described above. As
shown in Fig. 3B the recombinant dVV-YF (lane 1) expressed the
E protein in the infected cVero22 cells, as did the YFV-17D virus
(lane 4).
The recombinant viruses MVA-YF and dVV-YF were designed
as live vaccines for human use, and efficacy was assessed in a
mouse protection model. In the mouse and human organisms,
these vaccinia viruses do not replicate. Efficient YFV prME
expression also without replication of the vaccinia vector is
therefore a prerequisite for successful immunization. For this
reason, the expression patterns were also studied in a human and
in a mouse cell line, non permissive for both the recombinant
MVA-YF and dVV-YF. Mouse muscle (Sol8) or human (HeLa)
cells were infected with a MOI of 10 of MVA-YF or dVV-YF and
with the corresponding controls. Infected cells were incubated for
two days and total cell lysates were investigated by SDS-PAGE
and Western blot analysis using anti-YFV antiserum. The
expression in Sol8 muscle cells should reflect the target cell type
in the selected mouse challenge model in which mice are
immunized intramuscularly (i.m.). As shown in Fig. 3C, recom-
binant MVA-YF (lane 1) and dVV-YF (lane 2) expressed the E-
protein in comparable amounts. As expected, in the negative
controls (lanes 3–5) no YFV protein was detectable. In this setting,
E-protein expression by the YFV-17D positive control (lane 6) was
below the limit of detection. In HeLa cells representing the human
situation (Fig. 3D) again comparable amounts of E-protein were
found in MVA-YF (lane 1) and dVV-YF (lane 2) infections. The
YFV-17D infected cells (lane 6) yielded similar amounts of E-
protein. Thus, in humans vaccinated with non-replicating MVA-
YF or dVV-YF, correct expression of the YFV antigen at
significant levels can be expected.
Protection Studies in Mice
The capacity of recombinant MVA-YF and dVV-YF to protect
mice against a lethal i.c. challenge with YFV-17D virus was
analyzed. Balb/c mice were therefore immunized with a single
intramuscular injection of MVA-YF or dVV-YF over a dose range
of 1610
2 to 1610
5 tissue culture infectious dose 50% (TCID50).
Additionally, mice were immunized with 1610
6 TCID50 of wild-
type MVA, dVV or PBS as negative controls, and with 1610
4
TCID50 (equivalent to the human dose) of YFV-17D as positive
control. Mice were challenged i.c. with 1610
5 TCID50 per animal,
representing a more than 1000-fold LD50 of the vaccine strain
YFV-17D at day 21 post vaccination. The LD50 in nine week old
mice was determined to be approximately 83 TCID50 (data not
shown).
Protection was demonstrated to be clearly dependent on the
dose of the vaccinia-vectored vaccines, Fig. 4A shows the results
obtained with MVA-YF while Fig. 4B shows those of dVV-YF.
The highest dose of 1610
5 TCID50 per animal conferred full
protection. The overall protection by dVV-YF was somewhat
weaker than by the recombinant MVA-YF. At the dose of 1610
2
TCID50 the survival with MVA-YF (65%611.6) was significantly
(p,0.01) higher than with dVV-YF (24%610.3). All negative
control groups, injected with the wild-type vaccinia viruses or PBS,
showed survival rates of maximal 20%. As expected, complete
protection was also seen in groups immunized with YFV-17D
(Fig. 4C).
Neutralizing antibodies were analyzed on day 19 in pre-
challenge sera. After vaccination with a single dose, the PRNT50
titer was low. This was true for vaccinations with recombinant
viruses up to the highest and fully protective immunization doses,
but also with YFV-17D. Therefore, a further experiment was




7 TCID50 of MVA-YF or dVV-
YF or 10
4 and 10
6 TCID50 of YFV-17D virus as a positive control.
Additionally, mice were immunized with a double dose of 1610
7
TCID50 of the wild-type MVA or dVV vectors as negative
controls. Sera were collected at day 42 after the primary
immunization and analyzed for YFV neutralizing antibodies by
PRNT50 assay. Again, both recombinant vaccines induced 100%
protection after one application of 10
5 TCID50 (Table 1),
however no or only low PRNT50 titers were measureable even
at the highest administered dose of 10
7 TCID50. Only the YFV-
17D vaccine this time induced low, but measurable neutralization
titers after a single dose administration of 10
4 and 10
6 TCID50.
After a second vaccination with MVA-YF or dVV-YF,
neutralization titers were detectable in a dose-dependent fashion.
Here, the MVA-based vaccine showed on average somewhat
Figure 2. Double Immunostaining of infected chicken cells (DF-
1). MVA-YF (A), wild-type MVA (B) and MVA-YF/MVA spike control (C).
After 4 days infected cells were fixed, incubated with guinea pig anti
YFV-17D antiserum and anti-guinea pig IgG conjugated to peroxidase.
Expressors of prME were visualized as black plaques staining with DAB
solution with nickel. To detect MVA without prME expression, cells were
incubated with rabbit-anti-vaccinia virus serum and anti-rabbit perox-
idase-conjugated IgG antibody and subsequent staining with DAB
solution without nickel, resulting in brown plaques (prME non-
expressors).
doi:10.1371/journal.pone.0024505.g002
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titers were induced with the YFV-17D vaccine.
Protection of Balb/c mice by passive transfer of immune
sera
In the immunization experiments, full protection was achieved
with the recombinant vaccines at neutralizing antibody levels
below the limit of detection. To independently analyze the
contribution of neutralizing antibodies to protection high titer sera
were produced. Balb/c mice were immunized three times
intramuscularly with 10
7 TCID50 of MVA-YF, dVV-YF and
YFV-17D. In parallel, mice were immunized i.m. with a triple
dose of 10
7 TCID50 of the wild-type MVA or dVV vectors as
negative controls. These high i.m. injections did not cause any
signs of disease in the mice confirming that the vaccines are well
tolerated using this route. Sera were collected on day 63 after the
primary immunization and analyzed by PRNT50 assay.
Groups of six 8–9 weeks old mice were then injected
intraperitoneal (i.p.) with 150 ml of sera with the indicated
PRNT50 values (Table 2). Six hours after passive transfer these
groups and a control non-treated group were challenged i.c. with
10
5 TCID50 of YFV-17D. The data presented in Table 2
demonstrate that the mean survival time of treated and non-
treated groups were similar and passively transferred antibodies
induced only partial protection from lethal challenge. In this
model at least seventy to eighty percent of mice that received sera
of high titers (PRNT50 50–100) from MVA-YF immunized mice
survived, whereas all mice that received sera with the low titer
(PRNT50 10) died. Mice treated with high titer sera of dVV-YF
(PRNT50 70) and YFV-17D (PRNT50 100) immunized mice
showed survival rates of 27% and 25%, respectively. Low titer
treated mice (PRNT50 5–7) showed similar survival rates as control
groups. Differences between the performance of the sera from the
individual vaccines were not significant. In conclusion, a relatively
Figure 3. YFV prME protein expression under permissive (A and B) and non-permissive (C and D) conditions. (A) Western blot of
lysates from chicken cells (DF-1) infected with MVA-YF or the corresponding controls. MVA-YF (Lane 1), wild-type MVA (Lane 2), non-infected DF-1
cells (Lane 3), positive control YFV-17D infected DF-1 cells (17D, Lane 4), YFV-17D prepared from infected HeLa cells (17D control, Lane 5). (B) Western
blot of lysates from cVero22 cells infected with dVV-YF or the corresponding controls. dVV-YF (Lane 1), wild-type dVV (Lane 2), non-infected cVero22
cells (Lane 3), positive control YFV-17D infected cVero22 (17D, Lane 4), 17D control (Lane 5). Western blot of mouse muscle cells (Sol8, C) or human
cells (HeLa, D) infected with the recombinants or the corresponding controls. MVA-YF (Lane 1), dVV-YF (Lane 2), wild-type MVA (Lane 3), wild-type
dVV (Lane 4), non-infected Sol8 (C) HeLa (D) cells (Lane 5), cells infected with YFV-17D (17D, Lane 6), 17D control (Lane 7). The band around 55 kDa
marked ‘‘E’’ indicates the YFV envelope protein.
doi:10.1371/journal.pone.0024505.g003
MVA-Based Yellow Fever Live Vaccine
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24505good passive protection level of 70–80% was seen after passive
transfer with the MVA-YF-induced sera confirming the important
role of neutralizing antibodies in protection, however, suggesting
that full protection in the active immunizations is supported by the
T cell responses in this animal model.
Induction of envelope protein-specific T cell responses in
mice
While induction of a humoral immune response and generation
of neutralizing antibodies against the envelope protein represent
the major protective mechanism following vaccination with the
live YFV-17D vaccine [6,51], the cellular immune responses are
also thought to play an important role in protection against
infection [24,27–29]. Recently, the T cell responses induced by the
YFV-17D vaccine were characterized [29]. In the latter study,
BALB/c (H2d) mice were inoculated with the 17D vaccine strain
and CD8- and CD4-specific epitopes were investigated [29].
To compare the T-cell responses following MVA-YF or dVV-
YF vaccination to the YFV-17D vaccine, mice were immunized
twice (day 0 and day 21) with the vaccinia virus recombinants or
the corresponding controls. Splenocytes were prepared on day 28
and stimulated in vitro with CD8- and CD4-specific peptides
derived from the YFV envelope [29]. The percentages of IFN-c
producing T cells were determined by a FACS-based intracellular
cytokine assay. The results of CD4-specific responses of two
independent experiments obtained with the prME expressing
recombinants MVA-YF, dVV-YF and with the corresponding
controls are shown in Fig. 5A. Following stimulation with YFV E-
peptides E4-E6, the vectors dVV-YF and YFV-17D induced
comparable amounts of specific CD4 T cells. The highest
frequency of CD4 positive IFN-c producing T cells (0.16%) was
seen after recombinant MVA-YF immunization, the difference to
YFV-17D was however not significant (p.0.05). Mean responses
to the 15mer control peptide from influenza haemagglutinin were
,0.01% in all vaccination groups (data not shown).
The frequency of YFV-specific CD8 T cells induced by the
recombinants and controls upon in vitro stimulation with the YFV
E-peptides are shown in Fig. 5B. Up to 5% of the total CD8 T
cells responded to the immunodominant peptide E1. The highest
frequency of YFV-specific CD8 T cells were detected in the mice
immunized with the MVA recombinant, followed by dVV-YF.
CD8 T cell activation by the recombinants was higher than by the
YFV-17D vaccine. This difference was significant for MVA-YF
(p,0.001). Again, responses to the 9mer control peptide from
influenza were low in all groups (,0.1%, data not shown).
To verifythat the envelope-specific CD8T cells were functionally
active and kill target cells pulsed with specific YFV envelope
peptides, a cytotoxic T-lymphocyte (CTL) killing assay based on
fluorometrictechniques was used [52]. For this purpose,splenocytes
were incubated with peptide-presenting and dye-labeled target and
control cells. The reduction of the peptide-pulsed target cells versus
control cells after incubation with the splenocytes indicates the
presence of functional CTLs. As already seen in the CD8 IFN-c
assay, pulsing with E1 resulted in the highest responses (Fig. 5C).
CTL-specifickillingwascomparableforthe groupsimmunizedwith
MVA-YF (36%60), dVV-YF (48%623) and YFV-17D
(38.5%616.5). In summary, immunization with the MVA and
dVV recombinants and with YFV-17D vaccine induced compara-
ble levels of functionally competent CTLs.
Influence of pre-existing immunity on protection
It can be assumed that a subset of the human population
possesses immunity to vaccinia virus due to previous vaccinations,
either having received smallpox vaccination or being vaccinated
with MVA recombinant vaccines. Thus it is important to analyze
the influence of an already existing immunity to the vector on the
protection by the recombinant vaccine. To investigate if previous
exposure to vaccinia virus influences the effectiveness of the
recombinants, Balb/c mice were immunized first with 2610
6
TCID50 wild-type MVA (single and double dose) or vaccinia virus
Lister/Elstree, respectively. Three months later, animals were
vaccinated with a suboptimal double dose of 1610
3 TCID50 or
with the usually protective single dose of 1610
5 TCID50 of MVA-
YF, and the corresponding controls. Animals were finally
challenged with more than a 1000-fold LD50 YFV-17D. The
design of the experiment and the results are outlined in Table 3.
Figure 4. Protection studies in Balb/c mice. Animals were
vaccinated i.m. in a single dose scheme with the indicated doses of
(A) MVA-YF, (B) dVV-YF or with (C) the positive control YFV-17D (17D)
and the negative controls wild-type MVA, defective vaccinia virus (dVV)
or buffer (PBS). Mice were challenged i.c. 21 days later with 1610
5
TCID50 of YFV-17D vaccine strain and monitored for 14 days. Results are
the average of 3 individual experiments.
doi:10.1371/journal.pone.0024505.g004
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determine vaccinia virus-specific neutralizing antibody titers
(PRNT50).
In the groups immunized with a suboptimal double dose of
MVA-YF, no significant effect of the different pre-vaccinations
with wild-type viruses was seen (Tab. 3, groups 1–4). The
difference between protection achieved without (56% survival) or
with pre-existing immunity by wild-type VV immunization (VV
PRNT50 57–453, survival 36–56%) was not significant in all cases
(p.0.05).
Almost all mice (91%) which obtained a usually protective single
dose of 1610
5 TCID50 MVA-YF (Tab. 3, group 6) survived after
challenge if no pre-vaccination was performed. Also in this case,
pre-vaccination with a double dose of wild-type MVA (group 5)
did not result in significantly (p.0.05) decreased protection. In
summary, pre-existing anti-vaccinia virus immunity had no
Table 1. Protection and pre-challenge YFV plaque reduction neutralization titers in mice.




Single Dose Single Dose Double Dose
MVA-YF 2 11/17 (65) ,10
(6) n.d.
3 14/17 (82) ,10
(6) n.d.
4 16/17 (94) ,10 17




7 n.d. ,10 80
dVV-YF 2 4/17 (24) ,10
(6) n.d.
3 12/17 (71) ,10
(6) n.d.
4 16/18 (89) ,10 18.2
5 18/18 (100) ,10
(6) n.d.
6 n.d. 17.3 26.2
7 n.d. ,10 33
17D 4 17/17 (100) 13.2 120
6 - 54.3 381
MVA 6/7
(5) 5/21 (24) ,10 ,10
dVV 6/7
(5) 8/8 (0) ,10 ,10
Buffer - 5/22 (23) ,10 ,10
(1)Geometric mean titer;
(2)Results of two independent experiments;
(3)results of three independent experiments (except dVV);
(4)not determined;
(5)protection studies 10




Table 2. Protection and mean survival time after passive transfer.
Vaccine Passive Transfer Sera [PRNT50] Mean survival time [Days±SEM]
(1) Protection [Survivors/Total (%)]
(1)
MVA-YF 100 10.362.33 8/11 (73)
MVA-YF 50 11.061.00 9/11 (82)
MVA-YF 10 9.160.48 0/12 (0)
dVV-YF 70 9.861.03 3/11 (27)
dVV-YF 7 9.460.61 1/12 (8)
17D 100 9.860.83 3/12 (25)
17D 50 10.160.64 2/12 (17)
17D 5 10.860.58 0/12 (0)
MVA ,10 8.560.58 0/12 (0)
dVV ,10 9.760.48 0/12 (0)
- ,10 8.560.47 1/12 (8)
(1)results of two independent experiments.
doi:10.1371/journal.pone.0024505.t002
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against a lethal YFV-17D challenge.
Safety of MVA-YF and dVV-YF
To exclude the possibility that the introduction of the YFV
prME gene might alter the infectivity of the vaccinia virus vectors,
the safety profiles of the vaccines were tested. For this purpose,
Balb/c mice were challenged i.c. with high doses of 1610
5 to
1610
7 TCID50 MVA-YF, dVV-YF and with the corresponding
wild-type viruses. To compare also the safety profile of the
recombinants with the YFV-17D vaccine, 1610
1 to 1610
3
TCID50 of YFV-17D were administered intracerebrally. In the
vaccinia virus challenged groups, complete survival was seen even
with the highest dose of 1610
7 TCID50 (Fig. 6 A). Furthermore,
there was no difference between the wild-type vaccinia vectors and
the recombinants. In contrast, in YFV-17D challenged mice, a
very low dose of 1610
2 TCID50 YFV-17D induced 65% lethality
and 1610
3 TCID50 killed 100% of the mice (Fig. 6 B). In
conclusion the non-replicating vaccinia-based vaccines were safe
and very high doses administered intracerebrally did not kill the
mice. Furthermore, the introduction of the prME gene did not
altered the safety profile of the vaccinia vectors while low doses of
the YFV-17D vaccine as expected killed the mice after i.c.
administration.
Discussion
In order to combine the advantages of the existing YF live
vaccines with the excellent safety profile of MVA, we generated a
recombinant YF vaccine on the basis of this vector. In parallel, we
investigated an analogous vaccine on the basis of dVV, a vaccinia
virus that is rendered non-replicating by genetic engineering. This
virus retains its infectivity and expresses viral and integrated
foreign genes but fails to complete the replication cycle. The virus
can only be propagated to normal titers in an engineered
complementing cell line, but it is replication-deficient in any
natural host. Thus, dVV can be considered as a safe live vaccine
candidate similar to MVA [44]. The recombinant vaccines were
constructed by use of a synthetic sequence encoding the structural
proteins prME of the attenuated YFV-17D strain [47], optimized
for human codon-usage. The prME of the 17D strain was chosen
because the antigen is highly protective as proven by vaccination
campaigns in the past decades. Furthermore, use of identical
antigens ensures a valid comparison of the new VV based vaccine
concepts with the commercial YFV-17D live vaccine.
In the present study, we could show full protection of Balb/c
mice against a highly lethal challenge with YFV-17D (.1000-fold
mouse LD50) by the vaccinia-vectored vaccines. Surprisingly,
relatively low doses of 1610
5 TCID50 of recombinant MVA or
dVV, respectively, were sufficient to confer full protection after
only one vaccination. In a previous study reported by another
group [20], a single dose of 1610
7 PFU of the replication
competent vaccinia virus Western Reserve expressing the YFV-
17D prME could only partially protect mice against a 100-fold
LD50 challenge. Even after two inoculations, only 94% survival of
the animals was reported. In that study, however, the French
neurotropic YFV strain was used for challenge. Although in the
previous study, the LD50 dose was 10-fold lower, the use of the
French neurotropic as heterologous challenge strain, and the
different tropism of the viruses might have contributed to the
divergent protection results reported here. Nevertheless, the
superior immunogenicity achieved with MVA vectors compared
to replicating vaccinia virus Western Reserve strain [53] and use of
codon-optimized gene cassettes driven by a strong promoter might
Figure 5. Cellular immune response elicited against YFV E-
antigen. (A) FACS analysis of the number of IFN-c secreting CD4
+ T-
cells after two immunizations with MVA-YF, dVV-YF or the correspond-
ing YFV-17D (17D) positive or wild-type MVA and dVV negative
controls. Splenocytes from mice were stimulated with 15mer peptides
of the YFV E-protein, E57–71 (E4; black bars), E129–143 (E5; grey bars)
and E133–147 (E6; white bars). (B) FACS analysis of the number of IFN-c
secreting CD8
+ T cells after the two immunizations as indicated above.
Splenocytes from mice were stimulated with 9-mer peptides of the YFV
E-protein, E60–68 (E1; black bars), E330–338 (E2; grey bars), E332–340
(E3 white bars); ** p,0.001. (C) FACS analysis of cytotoxic killing of
peptide-pulsed target cells by specific CD8
+ T cells. Target cells were
loaded with 9mer peptides of the YFV E-protein, E60–68 (E1; black bars),
E330–338 (E2; grey bars), E332–340 (E3 white bars). The data are mean
values (+/2 SD) of two independent experiments.
doi:10.1371/journal.pone.0024505.g005
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with recombinant MVA expressing the Japanese encephalitis virus
(JEV) prME genes, three doses of 2610
6 infectious units were
necessary to protect mice against JEV challenge [54]. However, in
that case challenge was extremely high. Mice were challenged with
100 000 LD50, a dose that was 100-fold higher than in our study.
MVA-based vaccines have been used in clinical studies, for
instance, against HIV [32], tuberculosis [31], malaria [33] and
cancer [34]. In all of these studies, at least two doses were used.
The human dose of an MVA-based vaccine was 5610
7 to
5610
8 PFU as applied in recent clinical trials [31–34,55]. From
the results of our present animal studies, we speculate that the
MVA-YF vaccine might be efficient in a single dose regimen, at
comparable doses. It would offer significant cost and logistical
benefits, if MVA-YF could be administered in a single dose
scheme.
The induction of YFV-specific neutralizing antibodies in Balb/c
mice after a single dose immunization with MVA-YF and dVV-YF
was moderate. The PRNT50 titers at days 19 or 42, respectively,
were below or close to the limit of detection, even after the
administration of 10
7 TCID50. At the same time, a single dose of
10
5 TCID50 already induced 100% protection. Only after two
vaccinations were dose-dependent neutralization titers detectable.
These findings differ from previous results, where a single dose of
10
7 PFU of replicating recombinant vaccinia virus induced
measurable neutralizing antibodies to YFV in CD-1 mice [20].
However, in that study, also the YFV-17D control induced higher
neutralization titers than observed in our study. These differences
may be due to different mouse strains used or to assay specific
parameters. A head-to-head comparison of Balb/c and CD1 mice
was conducted in immunization experiments with inactivated
whole YFV-17D candidate vaccine [23]. In our study, two doses of
10
6 TCID50 MVA-YF resulted in similar neutralizing antibody
titers in Balb/c mice as reported for a proposed human dose of the
inactivated candidate vaccine [23]. Interestingly, with the
inactivated vaccine, higher antibody levels were published in
CD1 mice. Since the inactivated candidate vaccine was tested in
the mouse model only for immunogenicity but not for protective
efficacy, a comparison of the protective antibody levels between
the inactivated and the vaccinia vectored live vaccine is not
possible.
To explore the ability of neutralizing antibodies to account for
protection of mice from lethal challenge, passive transfer of serum
from vaccinated mice to naı ¨ve mice were performed. Mice which
received low titer sera and sera of wild-type MVA or dVV
Table 3. Immunization scheme, VV PRNT50 values prior to YF vaccination and survival of mice.
group 1st pre-Immun. 2nd pre-Immun.
VV PRNT50
[GMT]
(1) 1st Immun. 2nd Immun.
protection [Survivors/Total
(%)]
[day 0] [day 21] [day 82] [day 84] [day 104] [day 138]
1



















(3) MVA MVA 392
(1) MVA-YF (10
5) - 8/11 (73)
6
(3) -- ,20 MVA-YF (10
5) - 10/11 (91)
7
(2) -- ,20 17D (10
4) - 13/18 (72)
8
(2) -- ,20 Buffer - 1/16 (6)
(1)Geometric mean titer;
(2)results of three independent experiments;
(3)results of two independent experiments.
doi:10.1371/journal.pone.0024505.t003
Figure 6. Safety of recombinant candidate vaccines in BALB/c




7 TCID50 dose shown) of MVA-YF (bright grey line), dVV-YF (grey
line) and the corresponding controls wild-type MVA (dotted line) and
dVV (black line) and monitored for 21 days. (B) Mice were injected i.c.
with YFV-17D vaccine at doses of 1610
1 (bright grey line), 1610
2 (grey
line) or 1610
3 (dotted line), and monitored for 21 days.
doi:10.1371/journal.pone.0024505.g006
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Partial protection of mice was only achieved after passive transfer
of sera from MVA-YF, dVV-YF and YFV-17D immunized mice
with PRNT50 of about 100. This corresponds to titers of
approximately 10 in the bloodstream of animals, assuming that
the transferred serum is diluted approximately tenfold in mouse
blood volume [56]. In the active immunization model full
protection was conferred after vaccination with 1610
5 TCID50
of the recombinant candidate vaccines. At the same time the
neutralizing antibody titer was below the technical detection limit.
Based on the known role of neutralizing antibodies in flavivirus
protection, we assume that neutralizing antibodies below our
detection limit of ,10 were present. However, these data further
suggest that additional factors, such as the cellular immune
response contributes to protection.
The induction of the E-protein specific cellular immune
responses is considered to be an important factor of immunity
for the live YFV-17D vaccine. We present for the first time an
analysis of the cellular immunity to E-antigen induced by
recombinant non-replicating vaccinia viruses and a comparison
with the YFV-17D live vaccine. Both vaccinia virus-based vaccines
induced a strong cellular immune response eliciting particularly
high frequencies of antigen-specific CD8-T cells but induction of
antigen-specific IFN-c producing CD4 T cells could also be
demonstrated. Specific CD4 T cell levels were higher with the
MVA-YF vaccine than with the dVV-YF or YFV-17D vaccines,
which showed comparable responses.
Administration of the MVA-based vaccine also resulted in the
strongest induction of E-antigen specific IFN-c secreting CD8 T
cells followed by the dVV-based and YFV-17D vaccines. However,
comparable amountsofEprotein-specificCTLswereinducedbyall
three vaccines. In a previous study, no deleterious effects on the
protection following YFV-17D immunization were seen when CD8
knock-out mice were used [24]. This suggested that CD8 T cells do
not represent a critical component of the protection against lethal
encephalitis in mice. Nevertheless, CD8 T cells may contribute to
virus clearance in humans who develop viscerotropic disease. A
recent study analyzed the attributes of human CD8 T cell response
after YFV-17D vaccinination in humans and found broad
specificity, multiple function, robust proliferation, and long term
persistence, all characteristics of protective cellular immunity [25].
In our studies, surprisingly low doses of the vaccinia vectored
vaccines conferred protection at least as good as a full human dose
of the YFV-17D live vaccine. A possible explanation might be the
previously reported secretion of YFV recombinant subviral particles
(RSP) following prME expression by vaccinia vectors [20,57]. This
secreted particulate form of the antigen displays a surface structure
similar to natural YFV virions resulting in improved antigenicity. In
a previous study, DNA vaccines were compared that expressed
either the complete TBE prME, or a truncated form producing
soluble antigens that were unable to form particles. It was observed
that protection by the particulate form was far superior to the
soluble secreted form [58]. We speculate that the secretion of RSPs
by vaccinia vectored vaccines might also contribute to the good
protection levels observed in the current study.
A further advantage of using non-replicating poxviral vectors is
the well described safety profile [31,32,36,37,44]. MVA is well
tolerated in immune compromised [59,60] and in elderly persons
[61]. Using an in vivo safety assay, we showed that both vaccinia
recombinants are safe, even at a dose of 10
7 TCID50, when
administered intracerebrally. In contrast, a much lower dose of
10
3 TCID50, i.e. one tenth of the human dose of the YFV-17D
killed 100% of the mice, using the same route. The superior safety
of the vaccinia recombinants is probably due to the fact that the
recombinants do not undergo a complete replication cycle while
YFV-17D continues to propagate in the organism.
The effect of pre-existing antibodies to the vector in a part of the
human population due to prior vaccinia vaccinations has been
discussed extensively. Findings regarding the influence of anti-
poxviral immunity have been contradictory [62–65]. In our hands
pre-vaccinationwitha single dose of replicating vaccinia virus Lister
or with wild-type MVA followed by prime/boost immunization
with a suboptimal dose of MVA-YF had no measurable negative
influence on protection. Even though protection in mice pre-
immunized twice with wild-type MVA appeared diminished, the
difference was not significant compared to non pre-treated mice.
Nine months old mice used in the pre-immunization experiment
revealed decreased survival rates (56% and 91%) as compared to
nine weeks old mice (82% and 100%), which may be due to a less
effective immune system in aged mice (see e.g. refs. [66–68]).
Protection studies in the present work were performed using
intracerebral challenge with a fully lethal dose of a YFV vaccine
strain, similar to earlier studies [20,21]. Vaccine strains show
virulence similar to wild-type strains, if administered intracerebrally
[69].Theattenuated vaccine strain17Dwaschosenfori.c.challenge
for availability reasons and because of biosafety considerations.
Animal models reflecting the viscerotropic character of the human
disease have also been developed previously [23,70,71]. The
assessment of the recombinant candidate vaccines in a viscerotropic
model is desirable and will be a subject of further studies.
In summary, our data show that the non-replicating MVA-YF
and dVV-YF candidate vaccines induce both cellular and humoral
immune responses and protect mice from a multifold lethal
challenge with YFV-17D, suggesting their usefulness as effective
and safe live vaccines against yellow fever disease.
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